CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 1, 2018--
Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host
its fourth quarter and full-year 2017 investor update conference call
and webcast at 8:30 a.m. Eastern Time on Thursday, February 15, 2018.
Individuals interested in participating in the call should dial (877)
643-7155 (U.S. and Canada) or (914) 495-8552 (international)
using conference ID number 8489758. To access the webcast, please visit
the Investors section of Ironwood’s website at www.ironwoodpharma.com
at least 15 minutes prior to the start of the call to ensure adequate
time for any software downloads that may be required.
The call will be available for replay via telephone starting February
15, 2018 at approximately 11:30 a.m. Eastern Time, running through 11:59
p.m. Eastern Time on February 22, 2018. To listen to the replay, dial
(855) 859-2056 (U.S. and Canada) or (404) 537-3406 (international) using
conference ID number 8489758. The archived webcast will be available on
Ironwood’s website for 14 days beginning approximately one hour after
the call has completed.
About Ironwood Pharmaceuticals
(NASDAQ:IRWD) is a commercial biotechnology company focused on creating
medicines that make a difference for patients, building value for our
fellow shareholders, and empowering our passionate team. We are
commercializing two innovative primary care products: linaclotide, the
U.S. branded prescription market leader for adults with irritable bowel
syndrome with constipation (IBS‐C) or chronic idiopathic constipation
(CIC), and lesinurad, which is approved for the treatment of
hyperuricemia associated with gout in patients who have not achieved
target serum uric acid (sUA) levels with a medically appropriate daily
dose of a xanthine oxidase inhibitor (XOI) alone. We are also advancing
a pipeline of innovative product candidates in areas of significant
unmet need, including uncontrolled gastroesophageal reflux disease,
diabetic nephropathy, heart failure with preserved ejection fraction,
achalasia and sickle cell disease. Ironwood was founded in 1998 and is
headquartered in Cambridge, Mass. For more information, please visit www.ironwoodpharma.com
information that may be important to investors will be routinely posted
in both these locations.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180201006221/en/
Source: Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc.
Meredith Kaya, 617-374-5082
Director, Investor Relations and Corporate Communications